C4 Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
CCCC$3.15+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue from collaboration agreements | $35,947 | $35,584 |
| Operating expenses: | ||
| Research and development | 104,240 | 110,637 |
| General and administrative | 36,196 | 42,124 |
| Impairment loss on right-of-use asset | 10,733 | — |
| Restructuring | — | 2,437 |
| Total operating expenses | 151,169 | 155,198 |
| Loss from operations | (115,222) | (119,614) |
| Other income (expense), net | ||
| Interest and other income, net | 10,349 | 14,429 |
| Total other income, net | 10,349 | 14,429 |
| Loss before income taxes | (104,873) | (105,185) |
| Income tax expense | (121) | (131) |
| Net loss | $(104,994) | $(105,316) |
| Net loss per share - basic and diluted | $(1.27) | $(1.52) |
| Weighted-average number of shares - basic and diluted | 82,894,459 | 69,372,993 |
| Other Comprehensive income (loss): | ||
| Unrealized (loss) gain on marketable securities | (3) | 180 |
| Comprehensive loss | $(104,997) | $(105,136) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.